Immutep Announces Promising Outcomes for First-Line Treatment in PD-L1 Negative Head and Neck Squamous Cell Carcinoma Patients
Immutep Limited announced positive results from Cohort B of the TACTI-003 (KEYNOTE-PNC-34) Phase IIb trial, evaluating eftilagimod alfa (efti) combined with MSD’s anti-PD-1 therapy KEYTRUDA (pembrolizumab) as a first-line treatment for recurrent or metastatic head and neck squamous cell carcinoma (1L HNSCC) patients with negative PD-L1 expression. Dr. Robert Metcalf presented the updated efficacy and safety data during an oral presentation at the ESMO Virtual Plenary session on 11 July 2024.
The investigational immuno-oncology combinatio...
